{"id":"W2054614641","doi":"10.1111/j.1468-1293.2008.00660.x","title":"Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV‐infected, therapy‐naïve patients: results of the EPIC study (CCR100136)<sup>*</sup>","year":2009,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hamilton Health Sciences","funders":"GlaxoSmithKline","keywords":"Medicine; Lopinavir/ritonavir; Ritonavir; Lopinavir; Adverse effect; Pharmacokinetics; Population; Lamivudine; Dosing; Zidovudine; CCR5 receptor antagonist; Internal medicine; Gastroenterology; Nausea; Pharmacology; Viral load; Virology; Virus; Viral disease; Antiretroviral therapy; Hepatitis B virus; Receptor; Chemokine receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00196247,0.0005425742,0.0008909288,0.0001807906,0.0001670204,0.0004839741,0.0003632831,0.000469804,0.001276626],"category_scores_gemma":[0.001246796,0.0002735996,0.0006685883,0.0002238688,0.0003667481,0.0003226191,0.0001773882,0.0009847005,0.0002275245],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003636856,"about_ca_system_score_gemma":0.0004436372,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003645169,"about_ca_topic_score_gemma":0.0008794558,"domain_scores_codex":[0.9992077,0.0005484913,0.00004855196,0.0000594235,0.00006697846,0.00006891254],"domain_scores_gemma":[0.99923,0.0002765453,0.0002124143,0.00005144026,0.00003846324,0.000191185],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5143594,0.02751539,0.1086041,0.001038122,0.00283642,0.0004922491,0.0006237286,0.003334658,0.06648567,0.0002082432,0.002048952,0.2724531],"study_design_scores_gemma":[0.2045114,0.5871181,0.1905005,0.00009818208,0.001969591,0.001107649,0.00011383,0.002037602,0.008553815,0.0001404686,0.003786784,0.000062122],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9972904,0.001812337,0.0001161982,0.00007554263,0.000008274921,0.0001263963,0.0001174545,0.000009590383,0.0004438386],"genre_scores_gemma":[0.9975955,0.0008289054,0.0004553172,0.0002210583,0.00004529205,0.000110422,0.0003802017,0.000004337536,0.0003588503],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00196247,"threshold_uncertainty_score":0.01037866,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01032576043088261,"score_gpt":0.2569921573094452,"score_spread":0.2466663968785626,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}